AstraZeneca has announced significant progress in the development of a new blood pressure therapy, achieving its primary endpoint in a Phase 3 clinical trial. This breakthrough...
Regeneron Pharmaceuticals announced on October 25, 2023, that its investigational treatment, garetosmab, successfully met the primary endpoint in a Phase 3 clinical trial. This trial focused...
Shares of Abivax experienced a remarkable increase of over 400% on October 25, 2023, following the announcement of significant progress in its late-stage trials for obefazimod,...
